Saxon Interests Inc. Acquires 631 Shares of Eli Lilly and Company $LLY

Saxon Interests Inc. increased its stake in shares of Eli Lilly and Company (NYSE:LLY) by 120.2% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,156 shares of the company’s stock after purchasing an additional 631 shares during the quarter. Saxon Interests Inc.’s holdings in Eli Lilly and Company were worth $847,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in LLY. EFG Asset Management North America Corp. grew its holdings in Eli Lilly and Company by 20.8% during the third quarter. EFG Asset Management North America Corp. now owns 18,051 shares of the company’s stock valued at $13,762,000 after purchasing an additional 3,113 shares during the period. Bensler LLC raised its position in shares of Eli Lilly and Company by 4.1% during the third quarter. Bensler LLC now owns 18,667 shares of the company’s stock worth $14,243,000 after purchasing an additional 740 shares during the period. KPP Advisory Services LLC lifted its holdings in shares of Eli Lilly and Company by 9.9% during the 3rd quarter. KPP Advisory Services LLC now owns 3,884 shares of the company’s stock valued at $2,964,000 after purchasing an additional 349 shares in the last quarter. Generali Investments Towarzystwo Funduszy Inwestycyjnych grew its position in shares of Eli Lilly and Company by 5.5% in the 3rd quarter. Generali Investments Towarzystwo Funduszy Inwestycyjnych now owns 1,920 shares of the company’s stock valued at $1,465,000 after purchasing an additional 100 shares during the period. Finally, Riverwater Partners LLC increased its stake in Eli Lilly and Company by 11.0% during the 3rd quarter. Riverwater Partners LLC now owns 1,370 shares of the company’s stock worth $1,045,000 after purchasing an additional 136 shares in the last quarter. 82.53% of the stock is owned by institutional investors.

Analysts Set New Price Targets

LLY has been the topic of several recent research reports. HSBC reissued a “hold” rating and issued a $1,070.00 price target on shares of Eli Lilly and Company in a research note on Wednesday, December 10th. Scotiabank started coverage on shares of Eli Lilly and Company in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $1,165.00 price target on the stock. The Goldman Sachs Group upped their price objective on Eli Lilly and Company from $951.00 to $1,145.00 and gave the company a “buy” rating in a research note on Monday, December 15th. Truist Financial increased their price objective on shares of Eli Lilly and Company from $1,038.00 to $1,182.00 and gave the company a “buy” rating in a research report on Wednesday, November 19th. Finally, Sanford C. Bernstein reissued an “outperform” rating on shares of Eli Lilly and Company in a report on Friday, December 19th. Four equities research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, Eli Lilly and Company currently has an average rating of “Buy” and an average target price of $1,174.61.

Eli Lilly and Company Trading Down 0.1%

Shares of LLY stock opened at $1,063.34 on Tuesday. The stock’s fifty day simple moving average is $1,057.99 and its 200 day simple moving average is $883.36. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,133.95. The company has a quick ratio of 1.24, a current ratio of 1.55 and a debt-to-equity ratio of 1.71. The firm has a market capitalization of $1.01 trillion, a P/E ratio of 52.02, a P/E/G ratio of 0.80 and a beta of 0.35.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The business had revenue of $17.60 billion during the quarter, compared to the consensus estimate of $16.09 billion. During the same period in the prior year, the business posted $1.18 earnings per share. Eli Lilly and Company’s quarterly revenue was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, sell-side analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be paid a $1.73 dividend. The ex-dividend date is Friday, February 13th. This represents a $6.92 annualized dividend and a dividend yield of 0.7%. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. Eli Lilly and Company’s dividend payout ratio (DPR) is 29.35%.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.